RxDoctor Payments Data

Hemant Boolani, MD

Cardiovascular Disease · Topeka, KSNPI 1952557753

Payments from drug & device makers

$2,778in general payments, 2019–2025

Across 148 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$363
  • Actelion Pharmaceuticals US, Inc.$345
  • Novartis$337
  • Abbott$280
  • Edwards Lifesciences$214
  • E.r. Squibb & Sons, L.L.C.$193
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,67896%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,778 in reported general payments places this provider in the 50th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$244,285
Medicare patients
1,661
Services billed
4,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban367$421,036
XareltoRivaroxaban135$148,569
Repatha SureclickEvolocumab62$67,857
EntrestoSacubitril/Valsartan37$48,244
JardianceEmpagliflozin22$30,155
CorlanorIvabradine Hcl27$19,328
Atorvastatin Calcium834$8,050
Dofetilide41$8,016
Metoprolol Succinate679$7,788
Rosuvastatin Calcium336$6,162
Losartan Potassium536$5,638
Amiodarone Hcl125$3,752
Lisinopril533$3,327
Diltiazem 12hr ErDiltiazem Hcl13$3,268
Amlodipine Besylate586$2,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$421,036367 claims
Johnson & JohnsonXarelto$62$148,569135 claims
NovartisEntresto$337$48,24437 claims
AmgenCorlanor$363$19,32827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →